GORE® VIABAHN® VBX


Balloon Expandable Endoprosthesis

FLEXIBLE STRENGTH. PROVEN SUCCESS.

Demonstrated long-term durable clinical outcomes in complex aortoiliac occlusive disease (AIOD) treatment through **five years.**

Sustained clinical effectiveness through five years:

- 89.5% primary patency and 96.1% primary assisted patency per lesion¹
- 89.1% freedom from target lesion revascularization (fTLR) per subject¹



Kaplan Meier graph of primary patency with number of lesions at risk



This physician-initiated study enrolled 59 patients from three participating centers with patients followed out to **five years** and beyond.

DURABLE PATIENT BENEFIT VERSUS BASELINE BEYOND FIVE YEARS¹

B g % of patients improved ≥ 1 Rutherford category from baseline¹

improvement in mean resting ankle-brachial index (ABI) (P < .001, .95 mean ABI)^{*,1}

3x improvement in median WIQ measures sustained beyond five years in long-term follow-up cohort¹

	Pre-procedure	3 years	5 years ⁺
Walking distance	7 (N = 59)	25 (N = 39)	21 (N = 27)
Walking speed	3 (N = 59)	10 (N = 39)	9 (N = 27)
Stair climbing	3 (N = 50)	11 (N = 38)	9 (N = 27)

* (*P* < .001) Statistically significant change from pre-procedure.

† Median follow-up of 6.6 years.



Reference

 Holden A, Takele E, Hill A, et al. Long-term follow-up of subjects with aortoiliac occlusive disease treated with the VIABAHN VBX balloon expandable endoprosthesis. Presented at Cardiovascular & Interventional Radiological Society of Europe (CIRSE) 2022; September 10-14, 2022; Barcelona, Spain. CardioVascular & Interventional Radiology 2022;45:Supplement:S147. Abstract 301.1.

Consult Instructions for Use

eifu.goremedical.com

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. $R_{\rm Only}$

Products listed may not be available in all markets.

GORE, *Together, improving life*, VBX, VBX FLEX, VIABAHN and designs are trademarks of W. L. Gore & Associates. © 2022 W. L. Gore & Associates GmbH 22757249-EN NOVEMBER 2022

W. L. Gore & Associates, Inc. goremedical.com



Asia Pacific +65 67332882 Australia / New Zealand 1800 680 424 Europe 00800 6334 4673 United States Flagstaff, AZ 86003 800 437 8181 928 779 2771